-
市場
-
產品
-
資訊
-
Moo社區
-
課堂
-
查看更多
-
功能介紹
-
費用費用透明，無最低余額限制
投資選擇、功能介紹、費用相關信息由Moomoo Financial Inc.提供
- English
- 中文繁體
- 中文简体
- 深色
- 淺色
Nkarta (NASDAQ:NKTX) Downgraded by Oppenheimer
Nkarta (NASDAQ:NKTX) Downgraded by Oppenheimer
Oppenheimer downgraded shares of Nkarta (NASDAQ:NKTX – Get Rating) from an outperform rating to a market perform rating in a research note released on Thursday morning, Marketbeat reports.
A number of other research analysts have also weighed in on NKTX. Cantor Fitzgerald reaffirmed an overweight rating on shares of Nkarta in a research note on Wednesday, September 21st. Canaccord Genuity Group began coverage on shares of Nkarta in a report on Monday, October 10th. They issued a buy rating and a $25.00 price objective on the stock. Mizuho lowered their price objective on shares of Nkarta from $81.00 to $26.00 and set a buy rating on the stock in a report on Wednesday, November 16th. Finally, Canaccord Genuity Group began coverage on shares of Nkarta in a report on Monday, October 10th. They issued a buy rating and a $25.00 price objective on the stock. One equities research analyst has rated the stock with a hold rating and nine have given a buy rating to the company's stock. Based on data from MarketBeat.com, the company presently has a consensus rating of Moderate Buy and a consensus target price of $29.90.
Get Nkarta alerts:Nkarta Stock Performance
Shares of NKTX opened at $5.54 on Thursday. Nkarta has a twelve month low of $5.22 and a twelve month high of $20.35. The firm's 50 day moving average price is $9.73 and its two-hundred day moving average price is $12.45. The firm has a market cap of $270.41 million, a P/E ratio of -2.07 and a beta of -0.06.
Insider Buying and Selling
In other Nkarta news, CEO Paul J. Hastings sold 23,376 shares of Nkarta stock in a transaction on Wednesday, September 28th. The shares were sold at an average price of $13.03, for a total transaction of $304,589.28. Following the completion of the transaction, the chief executive officer now directly owns 250,959 shares of the company's stock, valued at $3,269,995.77. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. 5.60% of the stock is owned by corporate insiders.Hedge Funds Weigh In On Nkarta
A number of hedge funds and other institutional investors have recently added to or reduced their stakes in NKTX. Parkwood LLC bought a new stake in shares of Nkarta in the second quarter valued at about $31,000. Quantbot Technologies LP boosted its position in shares of Nkarta by 39.1% in the first quarter. Quantbot Technologies LP now owns 3,200 shares of the company's stock valued at $36,000 after acquiring an additional 900 shares during the period. Denali Advisors LLC bought a new stake in shares of Nkarta in the second quarter valued at about $38,000. Point72 Hong Kong Ltd bought a new stake in shares of Nkarta in the third quarter valued at about $46,000. Finally, Federated Hermes Inc. boosted its position in shares of Nkarta by 735.3% in the first quarter. Federated Hermes Inc. now owns 4,711 shares of the company's stock valued at $54,000 after acquiring an additional 4,147 shares during the period. 87.22% of the stock is owned by institutional investors.
About Nkarta
(Get Rating)
Nkarta, Inc, a a clinical-stage biopharmaceutical company, develops and commercializes cell therapies for cancer treatment. The company's approach for cellular immunotherapy involves chimeric antigen receptors on the surface of a natural killer (NK) cell that enable the cell to recognize specific proteins or antigens that are present on the surface of tumor cells.
Read More
- Get a free copy of the StockNews.com research report on Nkarta (NKTX)
- MarketBeat: Week in Review 12/19 – 12/23
- These Steelmakers Deserve A Place On Your 2023 Watch List
- Inflation Cools, Where Does The S&P 500 Go Now
- Cintas Beats Inflation With Operating Leverage
- Your Decision to Buy Palantir May Simply Be a Matter of Time
Receive News & Ratings for Nkarta Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nkarta and related companies with MarketBeat.com's FREE daily email newsletter.
Oppenheimer downgraded shares of Nkarta (NASDAQ:NKTX – Get Rating) from an outperform rating to a market perform rating in a research note released on Thursday morning, Marketbeat reports.
據Marketbeat報道，在週四上午發佈的一份研究報告中，奧本海默將恩卡塔(納斯達克代碼：NKTX-GET Rating)的股票評級從表現優於大盤下調至市場表現。
A number of other research analysts have also weighed in on NKTX. Cantor Fitzgerald reaffirmed an overweight rating on shares of Nkarta in a research note on Wednesday, September 21st. Canaccord Genuity Group began coverage on shares of Nkarta in a report on Monday, October 10th. They issued a buy rating and a $25.00 price objective on the stock. Mizuho lowered their price objective on shares of Nkarta from $81.00 to $26.00 and set a buy rating on the stock in a report on Wednesday, November 16th. Finally, Canaccord Genuity Group began coverage on shares of Nkarta in a report on Monday, October 10th. They issued a buy rating and a $25.00 price objective on the stock. One equities research analyst has rated the stock with a hold rating and nine have given a buy rating to the company's stock. Based on data from MarketBeat.com, the company presently has a consensus rating of Moderate Buy and a consensus target price of $29.90.
其他一些研究分析師也加入了對NKTX的看法。康託·菲茨傑拉德在9月21日星期三的一份研究報告中重申了對Nkarta股票的增持評級。Canaccel Genuity Group在10月10日星期一的一份報告中開始報道Nkarta的股票。他們對該股發佈了買入評級和25.00美元的目標價。瑞穗在11月16日週三的一份報告中將Nkarta的股票目標價從81.00美元下調至26.00美元，並對該股設定了買入評級。最後，Canaccel Genuity Group在10月10日星期一的一份報告中開始報道Nkarta的股票。他們對該股發佈了買入評級和25.00美元的目標價。一名股票研究分析師對該股的評級為持有，九名分析師對該公司股票的評級為買入。根據MarketBeat.com的數據，該公司目前的共識評級為適度買入，共識目標價為29.90美元。
Nkarta Stock Performance
Nkarta股票表現
Shares of NKTX opened at $5.54 on Thursday. Nkarta has a twelve month low of $5.22 and a twelve month high of $20.35. The firm's 50 day moving average price is $9.73 and its two-hundred day moving average price is $12.45. The firm has a market cap of $270.41 million, a P/E ratio of -2.07 and a beta of -0.06.
週四，NKTX的股價開盤報5.54美元。Nkarta的12個月低點為5.22美元，12個月高位為20.35美元。該公司的50日移動均線價格為9.73美元，200日移動均線價格為12.45美元。該公司市值為2.7041億美元，本益比為-2.07倍，貝塔係數為-0.06倍。
Insider Buying and Selling
內幕買賣
Hedge Funds Weigh In On Nkarta
對沖基金對Nkarta進行加碼
A number of hedge funds and other institutional investors have recently added to or reduced their stakes in NKTX. Parkwood LLC bought a new stake in shares of Nkarta in the second quarter valued at about $31,000. Quantbot Technologies LP boosted its position in shares of Nkarta by 39.1% in the first quarter. Quantbot Technologies LP now owns 3,200 shares of the company's stock valued at $36,000 after acquiring an additional 900 shares during the period. Denali Advisors LLC bought a new stake in shares of Nkarta in the second quarter valued at about $38,000. Point72 Hong Kong Ltd bought a new stake in shares of Nkarta in the third quarter valued at about $46,000. Finally, Federated Hermes Inc. boosted its position in shares of Nkarta by 735.3% in the first quarter. Federated Hermes Inc. now owns 4,711 shares of the company's stock valued at $54,000 after acquiring an additional 4,147 shares during the period. 87.22% of the stock is owned by institutional investors.
許多對沖基金和其他機構投資者最近增持或減持了NKTX的股份。Parkwood LLC在第二季度購買了Nkarta的新股，價值約3.1萬美元。Quantbot Technologies LP在第一季度將其在Nkarta股票的頭寸提高了39.1%。Quantbot Technologies LP在此期間額外購買了900股，現在擁有3200股該公司的股票，價值3.6萬美元。Denali Advisors LLC在第二季度購買了Nkarta的新股，價值約3.8萬美元。Point72 Hong Kong Ltd在第三季度購買了Nkarta的新股，價值約4.6萬美元。最後，聯合愛馬仕公司在第一季度將其持有的恩卡塔股票頭寸提高了735.3%。聯合愛馬仕公司在此期間增持了4,147股，目前持有該公司4,711股股票，價值54,000美元。87.22%的股份由機構投資者持有。
About Nkarta
關於恩卡爾塔
(Get Rating)
(獲取評級)
Nkarta, Inc, a a clinical-stage biopharmaceutical company, develops and commercializes cell therapies for cancer treatment. The company's approach for cellular immunotherapy involves chimeric antigen receptors on the surface of a natural killer (NK) cell that enable the cell to recognize specific proteins or antigens that are present on the surface of tumor cells.
Nkarta，Inc.是一家臨床階段的生物製藥公司，開發和商業化癌症治療的細胞療法。該公司的細胞免疫療法涉及自然殺傷(NK)細胞表面的嵌合抗原受體，使細胞能夠識別腫瘤細胞表面存在的特定蛋白質或抗原。
Read More
閱讀更多內容
- Get a free copy of the StockNews.com research report on Nkarta (NKTX)
- MarketBeat: Week in Review 12/19 – 12/23
- These Steelmakers Deserve A Place On Your 2023 Watch List
- Inflation Cools, Where Does The S&P 500 Go Now
- Cintas Beats Inflation With Operating Leverage
- Your Decision to Buy Palantir May Simply Be a Matter of Time
- 免費獲取StockNews.com關於NKTX的研究報告
- MarketBeat：回顧一週12/19-12/23
- 這些鋼鐵制造商理應在2023年觀察名單上佔有一席之地
- 通脹降溫，標普500指數何去何從
- Cintas以經營槓桿擊敗通脹
- 你買下Palantir的決定可能只是個時間問題
Receive News & Ratings for Nkarta Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nkarta and related companies with MarketBeat.com's FREE daily email newsletter.
接受《Nkarta Daily》的新聞和評級-在下面輸入您的電子郵件地址，通過MarketBeat.com的免費每日電子郵件時事通訊接收對Nkarta和相關公司的最新新聞和分析師評級的每日簡要摘要。
moomoo是Moomoo Technologies Inc.公司提供的金融資訊和交易應用程式。
在美國，moomoo上的投資產品和服務由Moomoo Financial Inc.提供，一家受美國證券交易委員會（SEC）監管的持牌主體。 Moomoo Financial Inc.是金融業監管局（FINRA）和證券投資者保護公司（SIPC）的成員。
在新加坡，moomoo上的投資產品和服務是通過Moomoo Financial Singapore Pte. Ltd.提供，該公司受新加坡金融管理局（MAS）監管(牌照號碼︰CMS101000) ，持有資本市場服務牌照 (CMS) ，持有財務顧問豁免（Exempt Financial Adviser）資質。本內容未經新加坡金融管理局的審查。
在澳大利亞，moomoo上的金融產品和服務是通過Futu Securities (Australia) Ltd提供，該公司是受澳大利亞證券和投資委員會(ASIC)監管的澳大利亞金融服務許可機構（AFSL No. 224663）。請閱讀並理解我們的《金融服務指南》、《條款與條件》、《隱私政策》和其他披露文件，這些文件可在我們的網站 https://www.moomoo.com/au中獲取。
在加拿大，透過moomoo應用程式提供的僅限訂單執行的券商服務由Moomoo Financial Canada Inc.提供，並受加拿大投資監管機構（CIRO）監管。
在馬來西亞，moomoo上的投資產品和服務是透過Moomoo Securities Malaysia Sdn. Bhd. 提供，該公司受馬來西亞證券監督委員會（SC）監管(牌照號碼︰eCMSL/A0397/2024) ，持有資本市場服務牌照 (CMSL) 。本內容未經馬來西亞證券監督委員會的審查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd.，Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc和Moomoo Securities Malaysia Sdn. Bhd., 是關聯公司。
風險及免責聲明
moomoo是Moomoo Technologies Inc.公司提供的金融資訊和交易應用程式。
在美國，moomoo上的投資產品和服務由Moomoo Financial Inc.提供，一家受美國證券交易委員會（SEC）監管的持牌主體。 Moomoo Financial Inc.是金融業監管局（FINRA）和證券投資者保護公司（SIPC）的成員。
在新加坡，moomoo上的投資產品和服務是通過Moomoo Financial Singapore Pte. Ltd.提供，該公司受新加坡金融管理局（MAS）監管(牌照號碼︰CMS101000) ，持有資本市場服務牌照 (CMS) ，持有財務顧問豁免（Exempt Financial Adviser）資質。本內容未經新加坡金融管理局的審查。
在澳大利亞，moomoo上的金融產品和服務是通過Futu Securities (Australia) Ltd提供，該公司是受澳大利亞證券和投資委員會(ASIC)監管的澳大利亞金融服務許可機構（AFSL No. 224663）。請閱讀並理解我們的《金融服務指南》、《條款與條件》、《隱私政策》和其他披露文件，這些文件可在我們的網站 https://www.moomoo.com/au中獲取。
在加拿大，透過moomoo應用程式提供的僅限訂單執行的券商服務由Moomoo Financial Canada Inc.提供，並受加拿大投資監管機構（CIRO）監管。
在馬來西亞，moomoo上的投資產品和服務是透過Moomoo Securities Malaysia Sdn. Bhd. 提供，該公司受馬來西亞證券監督委員會（SC）監管(牌照號碼︰eCMSL/A0397/2024) ，持有資本市場服務牌照 (CMSL) 。本內容未經馬來西亞證券監督委員會的審查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd.，Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc和Moomoo Securities Malaysia Sdn. Bhd., 是關聯公司。
- 分享到weixin
- 分享到qq
- 分享到facebook
- 分享到twitter
- 分享到微博
- 粘贴板
使用瀏覽器的分享功能，分享給你的好友吧